Ablexis Announces Licensing of the AlivaMab Mouse to NGM Biopharmaceuticals
January 04, 2018 16:09 ET
|
Ablexis, LLC
BURLINGAME, Calif., Jan. 04, 2018 (GLOBE NEWSWIRE) -- Ablexis, LLC, a biopharmaceutical company focused on licensing its AlivaMab Mouse technology for antibody drug discovery, today announced a...
Ablexis Announces Licensing of the AlivaMab Mouse to Five Prime Therapeutics
September 14, 2017 08:01 ET
|
Ablexis, LLC
BURLINGAME, Calif., Sept. 14, 2017 (GLOBE NEWSWIRE) -- Ablexis, LLC, a biopharmaceutical company focused on licensing its AlivaMab Mouse technology for antibody drug discovery, today announced a...
Ablexis Announces Perpetual License Agreement for AlivaMab Mouse with Janssen
February 14, 2017 08:30 ET
|
Ablexis, LLC
-- Ablexis Looks Forward to Establishing Additional Non-Exclusive Partnerships in 2017 -- BURLINGAME, Calif., Feb. 14, 2017 (GLOBE NEWSWIRE) -- Ablexis, LLC today announced a licensing agreement...
Ablexis Announces Perpetual License of the AlivaMab Mouse to Tri-Institutional Therapeutics Discovery Institute
January 12, 2017 12:07 ET
|
Ablexis, LLC
BURLINGAME, Calif., Jan. 12, 2017 (GLOBE NEWSWIRE) -- Ablexis, LLC announced today that it has entered into a non-exclusive, perpetual license agreement with the Tri-Institutional Therapeutics...